Publications

Select keywords to filter the posts for matching content:

Keywords
Topics
  • The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
    Schaper-Gerhardt, K., Gutzmer, R., Angela, Y., Zimmer, L., Livingstone, E., Schadendorf, D., Hassel, J. C., Weishaupt, C., Remes, B., Kubat, L., Spassova, I., Becker, J. C.
    Study

    BONEMET

    Year

    2024

    Keywords
    • immunotherapy
    • melanoma
  • Design and Rationale of MYOFLAME-19 RCT: MYOcardial protection to reduce inFLAMmatory heart disease due to COVID-19 Infection using CMR Endpoints
    V. O. Puntmann , D. Beitzke, A. Kammerlander, I. Voges, D. D. Gabbert, M. Doerr, B. Chamling, B. Bozkurt, J. C. Kaski, E. Spatz, E. Herrmann, G. Rohde, P. DeLeuw, L. Taylor, C. Windemuth-Kieselbach, C. Harz, M. Santiuste, L. Schoeckel, J. Hirayama, P. C. Taylor, C. Berry, E. Nagel
    Study

    MYOFLAME-19

    Year

    2024

    Keywords
    • cardiovascular
    • COVID-19
  • real-world use of teriflunomide in Germany and changes in treatment patterns over time
    B.-A. Kallmann, G. Zu Eulenburg, J.S. Kullmann, M. Mäurer
    Study

    TAURUS-MS II

    Year

    2024

    Keywords
    • multiple sclerosis
  • InspeCKD - Analysis of the use of diagnostics in patients at high risk for chronic kidney disease in German general practitioner (GP) practices
    C. Wanner, E. Schaeffner, T. Frese, C. Weber, P. Stahl, F. Scherg, F. Burckhardt, U. Opfermann, F. Radowsky, F. Mader
    Study

    InspeCKD

    Year

    2024

    Keywords
    • CKD
  • DETECT IPN: Real-World Experience with Automated Detection of Incidental Pulmonary Nodules in an All-Comer Population
    Johannes Dunsche, Hans-Ulrich Kauczor, Oyunbileg V. Stackelberg, Isabelle Ayx, Rimma Kondrashova, Jens Vogel-Claussen, Joana Lamché, Gerald Schmid-Bindert
    PMID: 10.4236/ojrad.2025.151002 Show Details link to full text
    Study

    DETECT IPN

    Year

    2025

    Keywords
    • lung cancer
  • Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
    E. Livingstone; H. Gogas; L. Kandolf-Sekulovic; F. Meier; T.K. Eigentler; M. Ziemer; P.A.M. Terheyden; A.H. Gesierich; R.A. Herbst; K.C. Kähler; D.C. Ziogas; Z. Mijuskovic; M. Garzarolli; C. Garbe; A. Roesch; S. Ugurel; R. Gutzmer; J.J. Grob; F. Kiecker; J. Utikal; C. Windemuth-Kieselbach; S. Eckhardt; L. Zimmer; D. Schadendorf
    PMID: 10.1016/j.ejca.2023.112941 Show Details link to full text
    Study

    ImmunoCobiVem

    Year

    2023

    Keywords
    • melanoma
  • Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
    Prof Jürgen C Becker, MD PhD; Prof Selma Ugurel, MD; Prof Ulrike Leiter, MD; Prof Friedegund Meier, MD; Prof Ralf Gutzmer, MD; Prof Sebastian Haferkamp, MD; Lisa Zimmer, MD; Elisabeth Livingstone, MD; Prof Thomas K Eigentler, MD; Prof Axel Hauschild, MD: Felix Kiecker, MD; Prof Jessica C Hassel, MD; Peter Mohr, MD; Michael Fluck, MD; Ioannis Thomas, MD; Marlene Garzarolli, MD; Imke Grimmelmann, MD; Konstantin Drexler, MD; Alexandra N Spillner, PhD; Sebastian Eckhardt, MS; Prof Dirk Schadendorf, MD
    Study

    ADMEC-O

    Year

    2023

    Keywords
    • immunotherapy
    • nivolumab
    • Merkel cell carcinoma
  • Design and Rationale of MYOFLAME-19 RCT: MYOcardial protection to reduce inFLAMmatory heart disease due to COVID-19 Infection using CMR Endpoints
    Valentina O Puntmann, Dietrich Beitzke, Andreas Kammerlander, Inga Voges, Dominik D Gabbert, Marcus Doerr, Bishwas Chamling, Biykem Bozkurt, Juan Carlos Kaski, Erica Spatz, Eva Herrmann, Gernot Rohde0, Philipp DeLeuw, Lenka Taylor, Christine Windemuth-Kieselbach, Cornelia Harz, Marta Santiuste, Laura Schoeckel, Juliana Hirayama, Peter C Taylor, Colin Berry, Eike Nagel
    Study

    MYOFLAME-19

    Year

    2024

    Keywords
    • cardiovascular
    • COVID-19
  • TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time
    Boris-Alexander Kallmann, Georg zu Eulenburg, Jennifer S. Kullmann, Mathias Mäurer
    PMID: 10.1177/17562864241252722 Show Details link to full text
    Study

    TAURUS-MS II

    Year

    2024

    Keywords
  • InspeCKD - Analysis of the use of diagnostics in patients at high risk for chronic kidney disease in German general practitioner (GP) practices
    Christoph Wanner, Elke Schaeffner, Thomas Frese, Christoph Weber, Philipp Stahl, Felix Scherg, Fabian Burckhardt, Ulrich Opfermann, Frank Radowsky, Frederik Mader
    PMID: 10.1007/s15006-024-3684-y Show Details link to full text
    Study

    inspeCKD

    Year

    2024

    Keywords
    • CKD
Follow:
Seite: 1/5